🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise worldwide, with figures suggesting in excess of 82 million infections annually. Notably increased rates are observed in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in the same week. This medication, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which combines an injection and a pill. The trial included over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have shared hope. Having a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.